Organization · Venture Capital
Aisling Capital
Aisling Capital is a New York-based investment firm focused on healthcare and life sciences, investing in biopharmaceuticals, medical devices, and healthcare services. Founded in 2000, it has raised over $1.8 billion across five funds.
Overview
What Aisling Capital does
What Aisling Capital is
Aisling Capital is a New York-based investment firm focused on healthcare and life sciences, investing in biopharmaceuticals, medical devices, and healthcare services. Founded in 2000, it has raised over $1.8 billion across five funds.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2000
- Approximate age
- About 26 years
- Structured capabilities
- Funder
- Last reviewed
- March 18, 2026
Official channels
Find Aisling Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
Aisling Capital as a funder
Investment thesis
Aisling Capital focuses on investing in companies that develop and commercialize healthcare products, services, and technologies, addressing unmet medical needs.
Focus narrative
Aisling Capital invests in both private and public companies within the life sciences sector. Their investment strategy includes seed and venture financing for development-stage companies, small-cap publicly traded equities, structured debt, royalty deals, and large-cap leveraged buyouts of profitable companies.
Value beyond capital
Aisling Capital adds value to its portfolio companies through its extensive industry experience, strategic guidance, and access to a broad network within the healthcare sector.
Focus and fit
- Stages
- Seed · Series A · Series B · Growth Equity
- Sectors
- Biotech · Healthcare · Medical Devices · Pharma Tech
- Regions
- United States
Availability
- Currently deploying
- Yes
Portfolio and track record
Portfolio context
Aisling Capital's portfolio includes notable companies such as Aclaris Therapeutics, Inc., a specialty pharmaceutical company focused on dermatology; ADMA Biologics, Inc., developing plasma-based biologics for infectious diseases; Aimmune Therapeutics, Inc., focused on treatments for food allergies; Ajax Health, a medical device platform; and Antios Therapeutics, which targets therapies for viral diseases.
Common questions
What to know about Aisling Capital
Upseed classifies Aisling Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 18, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.